Globus Med Inc Stock Price, News & Analysis

The merger between Globus Medical (GMED) and NuVasive (NUVA) will form a leading musculoskeletal technology company, enhancing innovation in patient care. Under the all-stock agreement, NuVasive shareholders will receive 0.75 shares of Globus Medical for each share held, implying a price of $57.72 and an equity value of $3.1 billion. The new entity aims to capitalize on a $50 billion market, with combined net sales growth projected at 6-8% for 2023. This transaction is expected to close mid-2023, pending regulatory and shareholder approval.

Globus Medical (NYSE:GMED) will announce its financial results for Q4 and full year ended December 31, 2022, after market close on February 21, 2023. Investors can access the release on the company's website. A teleconference will be held at 4:30 p.m. ET to discuss the results, with live access available through the Investors page. Participants can join via telephone after pre-registration. Globus Medical is recognized for its musculoskeletal solutions, focused on enhancing surgical outcomes. Further information about their products and initiatives can be found on their website.

Globus Medical, a leader in musculoskeletal solutions, reported Q3 2022 financial results with worldwide net sales of $254.1 million, marking a 10.6% increase year-over-year. U.S. net sales rose by 9.5%, and international sales surged by 17.7%. GAAP net income was $47.4 million, a 0.5% increase, with diluted EPS at $0.47. The company reaffirmed its full-year guidance of $1.025 billion in sales but lowered non-GAAP diluted EPS guidance to $2.03 due to unfavorable currency impacts. The company remains debt-free.

Globus Medical (NYSE:GMED) will announce its Q3 2022 financial results on November 8, 2022, after market close. A teleconference is scheduled for the same day at 4:30 PM ET, accessible via the company's investor website. This release will provide insights into the company's financial performance for the quarter ending September 30, 2022. Shareholders can listen to the live call and will have access to an audio archive afterward. For more details, visit the Globus Medical investor page.

Globus Medical reported its Q2 2022 financial results, achieving worldwide net sales of $263.6 million, a 5.0% increase year-over-year, with a 6.5% rise on a constant currency basis. GAAP net income rose to $54.6 million, a 31.4% increase from Q2 2021, with diluted EPS at $0.53. Notably, the Enabling Technologies sector saw a 41.7% growth to $29.4 million, fueled by strong demand for robotic systems. The company reaffirms its 2022 guidance of $1.025 billion in net sales and $2.10 non-GAAP diluted EPS.

Globus Medical (NYSE:GMED) will announce its second-quarter financial results for the period ending June 30, 2022, after market close on August 4, 2022. Investors can access the release on their website. A teleconference will be held the same day at 4:30 p.m. Eastern Time to discuss the performance with stakeholders. Interested participants can join via a webcast or telephone by pre-registering for access. The audio archive will be available post-call. Globus Medical specializes in musculoskeletal solutions and was founded in 2003.

Globus Medical (NYSE: GMED) announced the successful first surgeries using the Excelsius3D™ imaging platform, enhancing its existing ExcelsiusGPS® robotic navigation system. Surgeons from various hospitals performed these surgeries, highlighting the system's capabilities for minimally invasive procedures and improved surgical outcomes. The Excelsius3D™ provides a streamlined navigation workflow, offers multiple imaging modes, and reduces radiation exposure. This technology is now commercially available in the US, aiming to elevate patient care in spinal surgeries.

Globus Medical (NYSE: GMED) reported Q1 2022 financial results, with worldwide net sales of $230.5 million, a 1.4% year-over-year increase. GAAP net income was $38.1 million, reflecting a 16.0% decrease from the previous year, attributed to higher product development and marketing expenses. Diluted EPS stood at $0.37, down 13.1% from $0.44. The company reaffirmed its 2022 guidance, targeting $1.025 billion in net sales. Notably, U.S. Spine sales showed recovery, with record performance in March.

Globus Medical (NYSE:GMED) is set to release its financial results for Q1 ended March 31, 2022, on May 10, 2022, after market close. Investors can access the release on the company’s website, where a teleconference will follow at 4:30 p.m. ET to discuss performance with the investment community. Interested parties can join the call via phone or access it online. The company specializes in musculoskeletal solutions, aiming to enhance surgical outcomes.